4D-150

Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet AMD and DME and 4D-710 for cystic fibrosis After alignment with FDA and EMA on trial designs for the 4D-150 Phase 3 4FRONT program in wet AMD, 4FRONT-1 and 4FRONT-2 trials on track to initiate in Q1 2025 and Q3 2025 respectively Primary endpoint 52-week topline data for both 4FRONT-1 and 4FRONT-2 expected in H2 2027 Cash runway extended under updated operating plan; unaudited cash, cash equivalents and marketable securities of $506M as of December 31, 2024 expected to fund operations into 2028 EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced a strategically focused pipeline, updated Phase 3 4FRONT program plans, initial 4FRONT guidance and resulting updated cash runway guidance. “4DMT was founded to address the challenges posed by traditional AAVs and to bring genetic medicines to market to transform outcomes for millions of patients. Over 10 years we created a diverse pipeline to bring this vision closer to reality with seven named product candidates across three therapeutic areas utilizing three novel, clinically-validated vectors,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “We have prioritized two product candidates with the strongest clinical proof of concept and high potential to impact the most patients to fulfil our mission. In addition, our ongoing regulatory interactions support an efficient path to Biologics License Applications (BLA) for 4D-150 in both wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).” Strategically Focused Pipeline Core Programs: Updates & Upcoming Milestones Large Market Ophthalmology Focus 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, well tolerated, intravitreal injection. 4D-150 is being developed for wet AMD and DME, each of which affects millions of patients globally, with the goal of preserving vision and relieving patients from burdensome repeated bolus injections, which can total up to 12 per year. 4DMT will focus the majority of its R&D resources and operations on global development and pre-commercial planning for 4D-150 in wet AMD. 4D-150 for Wet AMD: Ongoing Phase 1/2 PRISM clinical trial currently in long-term follow-up: 52-week interim data from Phase 2b cohort of the PRISM clinical trial to be presented at Angiogenesis, Exudation, and Degeneration 2025 on Saturday, February 8, 2025 Corporate webcast to discuss data to be held on Monday, February 10, 2025 Phase 3 4FRONT program overview and updates: Trial designs and CMC plans aligned with U.S. Food & Drug Administration (FDA) under RMAT designation and European Medicines Agency (EMA) under PRIME designation, based on multiple interactions through December 2024 4FRONT-1 and 4FRONT-2 are on target to initiate in Q1 and Q3 2025, respectively 4FRONT-1 and 4FRONT-2 clinical trial design: Primary endpoint: best corrected visual acuity (BCVA) noninferiority of 4D-150 3E10 vg/eye to aflibercept 2mg Q8W Enrichment criteria: Randomization requires on study demonstration of aflibercept responsiveness Supplemental aflibercept injection criteria for 4D-150 arm optimized to protect primary BCVA endpoint and to maximize reduction of supplemental treatment burden; criteria to be disclosed prior to trial initiation. No supplemental injections allowed in control arm Target enrollment of 400 patients per trial Designed with ≥90% power for primary endpoint of BCVA noninferiority of 4D-150 versus aflibercept 2mg Q8 weeks (margin of 4.5 letters) and supports required program safety database for BLA submission 4FRONT-1 to enroll treatment naïve population and 4FRONT-2 to enroll both treatment naïve and previously treated population, diagnosed within the last six months Primary endpoint 52-week topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027 4D-150 for DME: Ongoing SPECTRA Part 1 follow-up continues: Announced positive 32-week interim data today in separate press release Results and next steps to be presented in a corporate webcast on February 10, 2025 52-week interim data update expected at a scientific conference in mid-2025 Announced regulatory update, in separate press release issued today, summarizing written FDA feedback. Based on review of SPECTRA and PRISM data to date, combined with data from the two planned Phase 3 clinical trials in the 4FRONT wet AMD program, a single Phase 3 trial of 300-400 patients is acceptable for BLA submission and the Company may directly proceed into Phase 3 (SPECTRA Part 2 no longer needed) Ongoing Phase 1/2 PRISM clinical trial currently in long-term follow-up: 52-week interim data from Phase 2b cohort of the PRISM clinical trial to be presented at Angiogenesis, Exudation, and Degeneration 2025 on Saturday, February 8, 2025 Corporate webcast to discuss data to be held on Monday, February 10, 2025 Phase 3 4FRONT program overview and updates: Trial designs and CMC plans aligned with U.S. Food & Drug Administration (FDA) under RMAT designation and European Medicines Agency (EMA) under PRIME designation, based on multiple interactions through December 2024 4FRONT-1 and 4FRONT-2 are on target to initiate in Q1 and Q3 2025, respectively 4FRONT-1 and 4FRONT-2 clinical trial design: Primary endpoint: best corrected visual acuity (BCVA) noninferiority of 4D-150 3E10 vg/eye to aflibercept 2mg Q8W Enrichment criteria: Randomization requires on study demonstration of aflibercept responsiveness Supplemental aflibercept injection criteria for 4D-150 arm optimized to protect primary BCVA endpoint and to maximize reduction of supplemental treatment burden; criteria to be disclosed prior to trial initiation. No supplemental injections allowed in control arm Target enrollment of 400 patients per trial Designed with ≥90% power for primary endpoint of BCVA noninferiority of 4D-150 versus aflibercept 2mg Q8 weeks (margin of 4.5 letters) and supports required program safety database for BLA submission 4FRONT-1 to enroll treatment naïve population and 4FRONT-2 to enroll both treatment naïve and previously treated population, diagnosed within the last six months Primary endpoint 52-week topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027 52-week interim data from Phase 2b cohort of the PRISM clinical trial to be presented at Angiogenesis, Exudation, and Degeneration 2025 on Saturday, February 8, 2025 Corporate webcast to discuss data to be held on Monday, February 10, 2025 Trial designs and CMC plans aligned with U.S. Food & Drug Administration (FDA) under RMAT designation and European Medicines Agency (EMA) under PRIME designation, based on multiple interactions through December 2024 4FRONT-1 and 4FRONT-2 are on target to initiate in Q1 and Q3 2025, respectively 4FRONT-1 and 4FRONT-2 clinical trial design: Primary endpoint: best corrected visual acuity (BCVA) noninferiority of 4D-150 3E10 vg/eye to aflibercept 2mg Q8W Enrichment criteria: Randomization requires on study demonstration of aflibercept responsiveness Supplemental aflibercept injection criteria for 4D-150 arm optimized to protect primary BCVA endpoint and to maximize reduction of supplemental treatment burden; criteria to be disclosed prior to trial initiation. No supplemental injections allowed in control arm Target enrollment of 400 patients per trial Designed with ≥90% power for primary endpoint of BCVA noninferiority of 4D-150 versus aflibercept 2mg Q8 weeks (margin of 4.5 letters) and supports required program safety database for BLA submission 4FRONT-1 to enroll treatment naïve population and 4FRONT-2 to enroll both treatment naïve and previously treated population, diagnosed within the last six months Primary endpoint 52-week topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027 Primary endpoint: best corrected visual acuity (BCVA) noninferiority of 4D-150 3E10 vg/eye to aflibercept 2mg Q8W Enrichment criteria: Randomization requires on study demonstration of aflibercept responsiveness Supplemental aflibercept injection criteria for 4D-150 arm optimized to protect primary BCVA endpoint and to maximize reduction of supplemental treatment burden; criteria to be disclosed prior to trial initiation. No supplemental injections allowed in control arm Target enrollment of 400 patients per trial Designed with ≥90% power for primary endpoint of BCVA noninferiority of 4D-150 versus aflibercept 2mg Q8 weeks (margin of 4.5 letters) and supports required program safety database for BLA submission 4FRONT-1 to enroll treatment naïve population and 4FRONT-2 to enroll both treatment naïve and previously treated population, diagnosed within the last six months Designed with ≥90% power for primary endpoint of BCVA noninferiority of 4D-150 versus aflibercept 2mg Q8 weeks (margin of 4.5 letters) and supports required program safety database for BLA submission Ongoing SPECTRA Part 1 follow-up continues: Announced positive 32-week interim data today in separate press release Results and next steps to be presented in a corporate webcast on February 10, 2025 52-week interim data update expected at a scientific conference in mid-2025 Announced regulatory update, in separate press release issued today, summarizing written FDA feedback. Based on review of SPECTRA and PRISM data to date, combined with data from the two planned Phase 3 clinical trials in the 4FRONT wet AMD program, a single Phase 3 trial of 300-400 patients is acceptable for BLA submission and the Company may directly proceed into Phase 3 (SPECTRA Part 2 no longer needed) Announced positive 32-week interim data today in separate press release Results and next steps to be presented in a corporate webcast on February 10, 2025 52-week interim data update expected at a scientific conference in mid-2025 Results and next steps to be presented in a corporate webcast on February 10, 2025 Pulmonology Program 4DMT’s proprietary A101 vector is the first known AAV vector to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis (CF) following aerosol delivery. Given A101-enabled product candidate 4D-710’s proof of delivery, safety data and initial clinical activity signals, and ongoing support from the Cystic Fibrosis Foundation and collaboration with Therapeutics Development Network, the Company intends to complete Phase 1 enrollment in H1 2025, approach the FDA with a pivotal trial proposal mid-2025, and evaluate additional funding options to further advance 4D-710 into late-stage development. 4D-710 for CF Lung Disease: Phase 1 AEROW enrollment completed in November 2024 (Cohorts 3 & 4 fully enrolled with n=3 each), follow-up ongoing; trial allows up to an additional 3 people with CF at these dose levels Interim data update expected to be presented in mid-2025 at a scientific conference, including available measurements of ppFEV1, CFQ-R-R (quality-of-life instrument), lung clearance index and serial airway biopsies and brushings collected at 4-8 weeks and beyond 12 months post-dosing Phase 1 AEROW enrollment completed in November 2024 (Cohorts 3 & 4 fully enrolled with n=3 each), follow-up ongoing; trial allows up to an additional 3 people with CF at these dose levels Interim data update expected to be presented in mid-2025 at a scientific conference, including available measurements of ppFEV1, CFQ-R-R (quality-of-life instrument), lung clearance index and serial airway biopsies and brushings collected at 4-8 weeks and beyond 12 months post-dosing Interim data update expected to be presented in mid-2025 at a scientific conference, including available measurements of ppFEV1, CFQ-R-R (quality-of-life instrument), lung clearance index and serial airway biopsies and brushings collected at 4-8 weeks and beyond 12 months post-dosing Programs with Reduced Capital Allocation While we believe the therapeutics below hold significant potential, at this time no further significant investment is expected on these programs, pending additional financing or partnerships. 4D-175 for geographic atrophy (preclinical with open IND) 4D-725 for alpha-1-antitrypsin deficiency lung disease (preclinical) 4D-310 for Fabry disease cardiomyopathy (ongoing Phase 1) Following a comprehensive review of its portfolio, the Company has decided to terminate the development of the early-stage rare disease clinical programs evaluating 4D-110 for choroideremia and 4D-125 for X-linked retinitis pigmentosa. Given the promising portfolio of product candidates and vectors owned and developed by 4DMT, 4DMT will not be investing additional capital into new preclinical product candidates at this time. Updated Financial Guidance As a result of its strategically focused pipeline, resource reallocation and discontinued future investment plans on non-core product candidates, the Company has extended its cash runway. Under the updated operating plan, based on unaudited cash, cash equivalents and marketable securities of $506M as of December 31, 2024, the Company now expects its current cash to fund operations into 2028. Cash runway includes full execution and topline 52-week data from 4FRONT-1 and 4FRONT-2 Phase 3 clinical trials in wet AMD, and ongoing early-stage development for DME and CF. Additionally, the Company will explore value-creating partnership opportunities and other strategic financing options. About 4DMT 4DMT is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Learn more at www.4DMT.com and follow us on LinkedIn. Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, and clinical benefits and market potential of 4DMT’s product candidates, as well as the plans, announcements, and related timing for the clinical development of, regulatory interactions regarding, and potential commercialization of our product candidates, including 4D-150 and 4D-710, and statements regarding our anticipated resource allocation and cash runway. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward looking statements. Contacts: Media: Katherine Smith Inizio Evoke Comms Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Corporate Finance Investor.Relations@4DMT.com

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level 3E10 vg/eye demonstrated strong signals of clinical activity with sustained gain of BCVA of +8.4 letters and reduction of CST of -194 µm from baseline through Week 32 3E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, with 0.6 mean supplemental injections per patient through Week 32 FDA aligned with proposed single Phase 3 clinical trial being acceptable for the basis of a BLA submission for 4D-150 in DME, based on review of data from SPECTRA and PRISM (wet AMD) clinical trials to date and planned global Phase 3 clinical development program for wet AMD EMERYVILLE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive topline interim data from Part 1 of the SPECTRA clinical trial evaluating 4D-150 in diabetic macular edema (DME) and alignment with the U.S. Food and Drug Administration (FDA) on registrational pathway for 4D-150 in DME. “The promising initial safety and clinical activity data of 4D-150 in DME patients, together with the promising results in wet age-related macular degeneration (wet AMD), reinforces the potential applicability of 4D-150 across multiple VEGF-driven retinal diseases,” said Carlos Quezada-Ruiz, M.D., FASRS, SVP, Therapeutic Area Head, Ophthalmology. “4D-150 represents a potentially transformative new therapeutic option for the approximately one million DME patients in the U.S. alone. 4D-150 has the potential to set a new backbone therapy providing multi-year sustained VEGF inhibition in the retina with a single, safe, intravitreal injection. If approved, 4D-150 could significantly reduce the need for frequent bolus injections and address the current real-world challenge of patient adherence to therapy, thereby leading to better disease management and vision outcomes.” Clinical Trial Design & Interim Data from 4D-150 SPECTRA Part 1 Clinical Trial (Data Cutoff of December 13, 2024): Objectives: Evaluate safety and tolerability and identify dose level for further evaluation Utilized stringent supplemental aflibercept criteria and enrolled patients with high central subfield thickness (CST) to maximize patient safety and assess initial clinical activity Study Population: 22 patients enrolled across 3 dose levels: 3E10 vg/eye (n=9), 1E10 vg/eye (n=12), 5E9 vg/eye (n=1); 1 patient in 1E10 vg/eye arm terminated the study due to death unrelated to 4D-150, prior to completion of a post-baseline assessment Safety (n=21): 4D-150 was well tolerated with no intraocular inflammation at any timepoint All patients completed the 16-week topical corticosteroid taper on schedule and remained completely off steroids No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions Efficacy Results Through 32 Weeks: 3E10 vg/eye arm: Sustained gain of best corrected visual acuity (BCVA) of +8.4 letters Sustained reduction of CST, as measured by optical coherence tomography (OCT), of -194 µm Supplemental injections: Post-aflibercept loading doses (3), 3E10 vg/eye achieved substantially fewer supplemental injections compared to 1E10 vg/eye and projected on-label aflibercept 2mg Q8W: Mean injections per patient: 3E10 vg/eye: 0.6, 1E10 vg/eye: 1.4, projected on-label aflibercept 2mg Q8W: 4.0 3E10 vg/eye demonstrated a reduction of 61% vs. 1E10 vg/eye 3E10 vg/eye demonstrated a reduction of 86% vs. projected on-label aflibercept 2mg Q8W 0-1 injections: 8 of 9 overall (3E10 vg/eye) vs. 5 of 10 (1E10 vg/eye, 1 patient missed Week 24-32 visits) Injection-free: 5 of 9 overall (3E10 vg/eye) vs. 2 of 10 overall (1E10 vg/eye) 5 of 8 in patients treated per protocol (3E10 vg/eye) Results to be presented in a corporate webcast on February 10, 2025 52-week interim data update expected at a scientific conference in mid-2025 Data slides can be found on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/ Utilized stringent supplemental aflibercept criteria and enrolled patients with high central subfield thickness (CST) to maximize patient safety and assess initial clinical activity 22 patients enrolled across 3 dose levels: 3E10 vg/eye (n=9), 1E10 vg/eye (n=12), 5E9 vg/eye (n=1); 1 patient in 1E10 vg/eye arm terminated the study due to death unrelated to 4D-150, prior to completion of a post-baseline assessment 4D-150 was well tolerated with no intraocular inflammation at any timepoint All patients completed the 16-week topical corticosteroid taper on schedule and remained completely off steroids No hypotony, endophthalmitis, vasculitis, choroidal effusions or retinal artery occlusions All patients completed the 16-week topical corticosteroid taper on schedule and remained completely off steroids 3E10 vg/eye arm: Sustained gain of best corrected visual acuity (BCVA) of +8.4 letters Sustained reduction of CST, as measured by optical coherence tomography (OCT), of -194 µm Supplemental injections: Post-aflibercept loading doses (3), 3E10 vg/eye achieved substantially fewer supplemental injections compared to 1E10 vg/eye and projected on-label aflibercept 2mg Q8W: Mean injections per patient: 3E10 vg/eye: 0.6, 1E10 vg/eye: 1.4, projected on-label aflibercept 2mg Q8W: 4.0 3E10 vg/eye demonstrated a reduction of 61% vs. 1E10 vg/eye 3E10 vg/eye demonstrated a reduction of 86% vs. projected on-label aflibercept 2mg Q8W 0-1 injections: 8 of 9 overall (3E10 vg/eye) vs. 5 of 10 (1E10 vg/eye, 1 patient missed Week 24-32 visits) Injection-free: 5 of 9 overall (3E10 vg/eye) vs. 2 of 10 overall (1E10 vg/eye) 5 of 8 in patients treated per protocol (3E10 vg/eye) Sustained gain of best corrected visual acuity (BCVA) of +8.4 letters Sustained reduction of CST, as measured by optical coherence tomography (OCT), of -194 µm Mean injections per patient: 3E10 vg/eye: 0.6, 1E10 vg/eye: 1.4, projected on-label aflibercept 2mg Q8W: 4.0 3E10 vg/eye demonstrated a reduction of 61% vs. 1E10 vg/eye 3E10 vg/eye demonstrated a reduction of 86% vs. projected on-label aflibercept 2mg Q8W 0-1 injections: 8 of 9 overall (3E10 vg/eye) vs. 5 of 10 (1E10 vg/eye, 1 patient missed Week 24-32 visits) Injection-free: 5 of 9 overall (3E10 vg/eye) vs. 2 of 10 overall (1E10 vg/eye) 5 of 8 in patients treated per protocol (3E10 vg/eye) 3E10 vg/eye: 0.6, 1E10 vg/eye: 1.4, projected on-label aflibercept 2mg Q8W: 4.0 3E10 vg/eye demonstrated a reduction of 61% vs. 1E10 vg/eye 3E10 vg/eye demonstrated a reduction of 86% vs. projected on-label aflibercept 2mg Q8W 8 of 9 overall (3E10 vg/eye) vs. 5 of 10 (1E10 vg/eye, 1 patient missed Week 24-32 visits) 5 of 9 overall (3E10 vg/eye) vs. 2 of 10 overall (1E10 vg/eye) 5 of 8 in patients treated per protocol (3E10 vg/eye) 4D-150 DME Phase 3 Regulatory Update & Next Steps 3E10 vg/eye has been selected as the Phase 3 dose Based on data generated to date for 4D-150 in both the SPECTRA and PRISM clinical trials, FDA is aligned that a single Phase 3 clinical trial, combined with data from the two planned Phase 3 clinical trials in the 4FRONT wet AMD program, would be acceptable as the basis of a BLA submission for 4D-150 in DME Per FDA feedback, the Company may proceed to Phase 3 (SPECTRA Part 2 no longer needed) and is aligned with key design elements of a Phase 3 clinical trial with approximately 300-400 patients total with a primary endpoint of BCVA noninferiority vs. on-label aflibercept 2mg (5 loading doses and Q8W), and revised supplemental injection criteria (less stringent compared to Part 1 SPECTRA, in line with prior successful Phase 3 DME clinical trials) Next steps for DME development to be presented in a corporate webcast on February 10, 2025 “The highly differentiated tolerability and promising clinical activity profile to date for 4D-150, and supportive feedback we received from the FDA in both wet AMD and DME, is a testament to 4D-150’s differentiated product design based on our proprietary R100 vector and our strong team, including our global Ophthalmology Advisory Board,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT. “The alignment with the FDA on the design and path forward for a single Phase 3 trial in DME is a positive step forward in our ability to realize 4D-150’s potential as a pipeline-in-a-product, which may unlock DME as a second large market indication shortly after wet AMD." About 4D-150 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection. 4D-150 utilizes our customized and evolved intravitreal vector, R100, which was invented at 4DMT through our proprietary Therapeutic Vector Evolution platform. 4D-150 is being developed for wet AMD and DME which both affect millions of patients globally, with the goal of freeing patients from burdensome injections while preserving vision. About DME DME, or diabetic macular edema, is a complication of diabetic retinopathy and is a highly prevalent disease with significant unmet medical need and poor treatment adherence. It is estimated that there are approximately one million individuals with DME in the U.S. according to published data. DME is characterized by inflammation swelling in the macula due to leakage from blood vessels, which can lead to vision loss. DME is typically treated with intravitreal anti-VEGF agents administered approximately every 4-12 weeks, although patient compliance with therapy is poor and results in high unmet medical need. About 4DMT 4DMT is a late-stage biotechnology company focused on unlocking the full potential of genetic medicines to treat large market diseases in ophthalmology and pulmonology. 4DMT’s proprietary invention platform, Therapeutic Vector Evolution, combines the power of directed evolution with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors for use in our wholly owned and partnered product candidates. Our lead program 4D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) targeted to the retina with a single, safe, intravitreal injection. Our second core program is 4D-710, which is the first known genetic medicine to demonstrate, in the lungs of people with cystic fibrosis (CF), successful delivery and expression of the CFTR transgene and initial clinical activity signals after aerosol delivery of a gene therapy. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of our product candidates are in clinical or preclinical development and have not yet been approved for marketing by the FDA or any other regulatory authority. No representation is made as to the safety or effectiveness of our product candidates for the therapeutic uses for which they are being studied. Learn more at www.4DMT.com and follow us on LinkedIn. Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding the therapeutic potential, and clinical benefits and market potential of 4DMT’s product candidates, as well as the plans, announcements, and related timing for the clinical development of and regulatory interactions regarding 4D-150. The words "may," “might,” "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," “expect,” "estimate," “seek,” "predict," “future,” "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including risks and uncertainties that are described in greater detail in the section entitled "Risk Factors" in 4D Molecular Therapeutics’ most recent Quarterly Report on Form 10-Q filed on November 13, 2024 as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent 4D Molecular Therapeutics' views only as of today and should not be relied upon as representing its views as of any subsequent date. 4D Molecular Therapeutics explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Contacts: Media: Katherine Smith Inizio Evoke Comms Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Corporate Finance Investor.Relations@4DMT.com